M.454 The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: A Greace substudy

Athyros, V.G.; Mikhailidis, DP; Papageorgiou, Angeliki; Symeonidis, A.; Pehlivanidis, AN; Bouloukos, V.; Elisaf, Moses

doi:10.1016/s1567-5688(04)90452-2

Cited by 7 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reduction in LDL-C was 50.1% and 35.2% for the 40 and 10 mg groups, respectively. Similarly, in the GREACE study [139,140] (see above) the reduction in LDL-C was 46% and this was associated with a significant fall in serum creatinine level. These findings suggest that a considerable decrease in LDL-C may be associated with a fall in serum creatinine.…”

Section: Atorvastatin and Other Statinsmentioning

confidence: 82%

“…In the GREACE trial [139,140] intensive treatment with atorvastatin to achieve the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) lowdensity lipoprotein-cholesterol (LDL-C) target levels (100 mg/dl; 2.6 mmol/l) was compared with 'usual care' in patients with coronary heart disease. Atorvastatin use was associated with a significant fall in SUA and serum creatinine levels when compared with the 'usual care' group, where LDL-C levels were not significantly altered.…”

Section: Atorvastatin and Other Statinsmentioning

confidence: 99%

See 1 more Smart Citation

Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia

Daskalopoulou

Tzovaras²,

Mikhailidis³

et al. 2005

CPD

Self Cite

View full text Add to dashboard Cite

Beyond allopurinol and the well-established uricosuric drugs, several other agents can decrease serum uric acid (SUA) levels, such as losartan, fenofibrate and some non-steroidal anti-inflammatory drugs (NSAIDs). Some of these drugs increase renal urate excretion. Hyperuricaemia and gout are common problems (at least 1% of Western men are affected by gout). Raised SUA levels increase the incidence of acute gout and renal calculi. Hyperuricaemia may also predict an increased risk of vascular events. Therefore, lowering SUA levels is of clinical relevance. In this review we consider the effect on SUA levels of drugs that are prescribed for indications other than treating hyperuricaemia. These drugs may obviate the need for specific treatment (e.g. allopurinol) aimed at lowering SUA levels. Furthermore, because hyperuricaemic patients may already be on several drugs (e.g. due to associated dyslipidaemia, hypertension and/or arthritis) compliance may be improved by avoiding additional medication. The potential for adverse effects associated with polypharmacy would also be decreased.

show abstract

Section: Atorvastatin and Other Statinsmentioning

confidence: 82%

Section: Atorvastatin and Other Statinsmentioning

confidence: 99%

Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia

Daskalopoulou

Tzovaras²,

Mikhailidis³

et al. 2005

CPD

Self Cite

View full text Add to dashboard Cite

show abstract

“…It follows, that the greatest risk reduction was seen in those with the biggest fall in LDL-C accompanied by the biggest rise in HDL-C [9]. In other post-hoc analyses of the GREACE study, we showed that atorvastatin improved renal function and this effect was partly related to the statin-induced rise in HDL-C levels [52,53].…”

Section: Clinical Studiesmentioning

confidence: 50%

High Density Lipoprotein Cholesterol and Statin Trials

Kakafika

Athyros²,

Τζιόμαλος³

et al. 2008

CMC

View full text Add to dashboard Cite

Epidemiological studies show that high density lipoprotein cholesterol (HDL-C) levels are inversely related to the risk of vascular events. Statins are the most widely prescribed drugs for the treatment of dyslipidaemias and their use for the prevention of vascular events is evidence based. Statins raise HDL-C but this effect seems to vary considerably between studies. We searched the literature to assess the relationship between statin-induced increases in HDL-C levels and surrogate and/or clinical endpoints. Based on the existing evidence, it is difficult to determine how much reduction, if any, in vascular risk is attributable to a statin-induced increment in HDL-C levels. Whether a statin that beyond its LDL-C lowering effect also raises HDL-C has additional benefits in the prevention of vascular events remains to be established.

show abstract

“…Renal function was examined in this study using Cockcroft-Gault derived creatinine clearance (CrCl) values. 11 The mean CrCl at entry was 77 ml/min. Patients on atorvastatin showed a 12% rise in CrCl, patients on other statins a 4.9% rise in CrCl, and statin free patients a 5.2% fall in CrCl over 36 months of follow up.…”

mentioning

confidence: 96%

“…11 ''Because the similarities between atherosclerosis and glomerulosclerosis are compelling, it stands to reason that the beneficial effects of statins on cardiovascular disease may also be generalised to the kidney''…”

mentioning

confidence: 99%